



Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, September 22, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of October 1, 2022.

1. Corporate Reorganization (see attached organization chart)

New establishment of the Academia Collaboration Office

The Academia Collaboration Office will be newly established within the Integrated Disease Care Division to strive to resolve issues affecting society in various fields through the integration of know-how concerning industry-academia collaboration, and the further promotion of partnerships involving Shionogi's internal value chain and academia, in the infectious disease, psychoneurological diseases and pain.

2. Personnel Reassignments (Effective; October 1, 2022)

New Position	Name	Present Position
Healthcare Business Supervisory Unit		
Senior Director, Integrated Disease Care Division Academia Collaboration Office	Hiroyuki Yoshida	Integrated Disease Care Division

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>

SHIONOGI Divisions (October 1, 2022)

